Dai et al. (2017) also reported that combining ENO1 autoantibodies with carcinoembryonic antigen and cytokeratin 19 fragment in a diagnostic panel increased diagnostic sensitivity for non-small cell lung cancer. Another study detected ENO1 autoantibodies at higher frequencies in patients with early stage lung cancer compared to late stage patients (Zhang et al., 2018). Here, ENO1 is linked to lung carcinoma.